Primary Pharmacology of CB213, a LAG-3-PD1 Co-targeting Humabody™
Time: 2:00 pm
day: Day One
Details:
- CB213 is engineered to engage LAG-3 particularly on PD1 expressing cells
- Human ex vivo and mouse syngeneic in vivo studies illustrate CB213 anti-tumor activity
- Pharmacokinetics studies in non-human primates suggest weekly or biweekly clinical dosing of CB213
